Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) Operating Expenses: 2020-2023

Historic Operating Expenses for Immuneering (IMRX) over the last 4 years, with Dec 2023 value amounting to $16.3 million.

  • Immuneering's Operating Expenses rose 16.56% to $16.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $58.4 million, marking a year-over-year increase of 12.54%. This contributed to the annual value of $58.4 million for FY2023, which is 12.54% up from last year.
  • Per Immuneering's latest filing, its Operating Expenses stood at $16.3 million for Q4 2023, which was up 17.06% from $13.9 million recorded in Q3 2023.
  • Immuneering's Operating Expenses' 5-year high stood at $16.3 million during Q4 2023, with a 5-year trough of $3.5 million in Q2 2020.
  • Moreover, its 3-year median value for Operating Expenses was $13.1 million (2022), whereas its average is $12.1 million.
  • Data for Immuneering's Operating Expenses shows a peak YoY surged of 140.32% (in 2021) over the last 5 years.
  • Over the past 4 years, Immuneering's Operating Expenses (Quarterly) stood at $6.0 million in 2020, then soared by 84.12% to $11.1 million in 2021, then climbed by 26.01% to $14.0 million in 2022, then increased by 16.56% to $16.3 million in 2023.
  • Its Operating Expenses stands at $16.3 million for Q4 2023, versus $13.9 million for Q3 2023 and $13.5 million for Q2 2023.